2008-06-17 02:19:16 -

With such dramatic changes to the drug safety environment in the last decade, it is clear that highly effective pharmacovigilance and risk management is critical for the current and future success of all biopharmaceutical companies. This presentation will examine the current environment including new expectations, new legislation, funding shifts and data transparency standards. Following will be perspectives and insights on

the innovations that can bring transformation in pharmacovigilance - including partnership approaches to PV, opportunities for optimizing safety in clinical trials, and alternative models for drug development and launch. For those organizations that can seize these opportunities to create the next generation of pharmacovigilance, there is a tremendous opportunity to both serve patients and create value. Dr. Ray will highlight critical new importance of pharmacovigilance and risk management for successful drug development. He will provide some insights on the new opportunities for high performance in pharmacovigilance, with cutting-edge examples of innovation in pharmacovigilance, and elaboration on the new globalization of pharmacovigilance standards.

The conference brings together leaders, directors, vice presidents, heads, managers, supervisors, and CROs from all over the world to collaborate and discuss the latest developments in clinical trial operations and logistics and covers clinical trials in emerging markets, first-in-man clinical trials, pediatric clinical trials, material storage, distribution, site selection, patient recruitment and retention, technology in clinical trials and case studies of running global clinical trials.
For more information including a detailed agenda, exhibitor opportunities and registration information visit gtcbio.com/conferenceDetails.aspx?id=127.